United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting
PREF-NET
A Cross-Sectional Patient-Reported Study To Assess The Patient Preference Of Treatment Administration Setting, Impact On Health-Related Quality Of Life, Work Productivity, Wider Societal Costs And Healthcare Utilisation For Patients With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Prescribed Somatuline® Autogel® In A Homecare Setting and Hospital Setting.
1 other identifier
observational
80
1 country
5
Brief Summary
The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2021
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 23, 2020
CompletedFirst Posted
Study publicly available on registry
December 2, 2020
CompletedStudy Start
First participant enrolled
April 27, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 5, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 5, 2022
CompletedDecember 17, 2024
December 1, 2024
1.1 years
September 23, 2020
December 13, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Patient preferences of treatment administration setting (homecare or hospital)
Survey responses of patient experience of injections at home and compared to responses of patient experience of injections when given in hospital
Baseline
Secondary Outcomes (8)
Demographic characteristics of enrolled patients with GEP-NETs
Baseline
Clinical characteristics of enrolled patients with GEP-NETs
Baseline
Patient-reported impact on healthcare resource use
Baseline
Patient-reported impact on wider societal costs
Baseline
Patient-reported work productivity
Baseline
- +3 more secondary outcomes
Study Arms (2)
Online Survey
One-to-one interviews
Eligibility Criteria
UK patients with NET receiving Somatuline Autogel injections at home
You may qualify if:
- Patients with a diagnosis of GEP-NETs
- Patients on prescribed lanreotide Autogel®;
- Patients who have switched from hospital to homecare administration setting at least 2 months ago
- Patients judged to be on a stable dose; 120mg for tumour control or \>1 injection at same dose for symptom control
You may not qualify if:
- Patients who decline or lack capacity to consent to participate in the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ipsenlead
Study Sites (5)
University Hospitals Birmingham NHS Foundation Trust
Birmingham, B15 2GW, United Kingdom
Cardiff and Vale University LHB
Cardiff, CF14 4HH, United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust
Coventry, CV2 2DX, United Kingdom
Liverpool University Hospitals NHS Foundation Trust
Liverpool, L7 8XP, United Kingdom
Royal Free London NHS Foundation Trust
London, NW3 2QG, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Ipsen Medical Director
Ipsen
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 23, 2020
First Posted
December 2, 2020
Study Start
April 27, 2021
Primary Completion
June 5, 2022
Study Completion
June 5, 2022
Last Updated
December 17, 2024
Record last verified: 2024-12